An effort by Sanofi (SNY) to transform its dengue vaccine into a blockbuster product has, instead, turned into a scandal for the drug maker and a public health crisis in the Philippines, where the government is investigating why the vaccine was so widely adopted, despite studies suggesting its use would not be appropriate for everyone.

The issue erupted last week when the company disclosed that a new analysis found its Dengvaxia vaccine could actually make future cases of the mosquito-borne virus more severe in people who were not previously infected. And so, Sanofi changed the product labeling to limit use to people who were not exposed to Dengue in the past.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy